Identification and characterisation of a prototype for a new class of competitive PPARγ antagonists

European Journal of Pharmacology
Tilo KnapeAndreas von Knethen

Abstract

Understanding of the physiological role of peroxisome proliferator-activated receptor gamma (PPARγ) offers new opportunities for the treatment of cancers, immune disorders and inflammatory diseases. In contrast to PPARγ agonists, few PPARγ antagonists have been studied, though they do exert immunomodulatory effects. Currently, no therapeutically useful PPARγ antagonist is commercially available. The aim of this study was to identify and kinetically characterise a new competitive PPARγ antagonist for therapeutic use. A PPARγ-dependent transactivation assay was used to kinetically characterise (E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl)benzyl)oxy)-benzylidene)-hexanoic acid (MTTB) in kidney, T and monocytic cell lines. Cytotoxic effects were analysed and intracellular accumulation of MTTB was assessed by tandem mass spectrometry (LC-MS/MS). Potential interactions of MTTB with the PPARγ protein were suggested by molecular docking analysis. In contrast to non-competitive, irreversible inhibition caused by 2-chloro-5-nitrobenzanilide (GW9662), MTTB exhibited competitive antagonism against rosiglitazone in HEK293T and Jurkat T cells, with IC50 values in HEK293T cells of 4.3µM and 1.6µM, usin...Continue Reading

References

Jul 1, 1977·The Journal of General Virology·F L GrahamR Nairn
Mar 15, 1988·International Journal of Cancer. Journal International Du Cancer·H W Ziegler-HeitbrockG Riethmüller
Jul 19, 1994·Proceedings of the National Academy of Sciences of the United States of America·S A KliewerR M Evans
Oct 1, 1995·Current Opinion in Genetics & Development·P TontonozB M Spiegelman
Feb 26, 2000·Journal of Medicinal Chemistry·T M WillsonB R Henke
Oct 24, 2000·Trends in Endocrinology and Metabolism : TEM·J M Olefsky, A R Saltiel
Mar 10, 2001·Recent Progress in Hormone Research·S A KliewerT M Willson
Sep 1, 2001·Trends in Molecular Medicine·M B SpornD J Mangelsdorf
Dec 1, 2001·Science·A ChawlaD J Mangelsdorf
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
May 29, 2004·Trends in Pharmacological Sciences·Shamina M Rangwala, Mitchell A Lazar
Oct 14, 2004·Cell·Bruce M Spiegelman, Reinhart Heinrich
Apr 30, 2005·Trends in Pharmacological Sciences·Joel P BergerPeter T Meinke
Jul 28, 2005·Diabetes·Bart Staels, Jean-Charles Fruchart
Apr 14, 2006·Endocrine, Metabolic & Immune Disorders Drug Targets·B L Balint, L Nagy
Sep 1, 2006·Trends in Endocrinology and Metabolism : TEM·Gabriel Pascual, Christopher K Glass
Feb 28, 2007·The Journal of Cell Biology·Andreas von KnethenBernhard Brüne
Apr 17, 2007·Biochimica Et Biophysica Acta·Mercedes Ricote, Christopher K Glass
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Oct 17, 2007·Structure·John B BruningPatrick R Griffin
Dec 2, 2008·Nature·Vikas ChandraFraydoon Rastinejad
Apr 8, 2011·American Journal of Respiratory and Critical Care Medicine·Martina Victoria SchmidtAndreas von Knethen
Jul 30, 2011·Bioorganic & Medicinal Chemistry Letters·Mairi SimeDavid J Virley

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.